Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...

After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...

A $140 million fund has been launched by Coefficient Giving, a health-focused philanthropic organisation, to fund R&D into ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant ...

Digital medicine specialist Newel Health has formed an alliance with packaging group Gerresheimer to help pharma companies ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant ovarian ...

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8 billion. At a stroke, the deals to acquire Curevo, LimmaTech ...

Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...

Johnson & Johnson's $14.6 billion takeover of Intra-Cellular Therapies (ICT) earlier this year largely revolved around the potential for Caplyta in depression – and it has just scored FDA approval in ...